Q2 2026 saw 38% revenue growth, driven by strong demand, a one-time CMS benefit, and broad-based product expansion. Guidance for full-year sales and expenses was raised, reflecting robust performance, new product launches, and the Vega Therapeutics acquisition.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.